Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
Proponents believe the Million European Genomes Alliance will spur research, stimulate the life sciences economy, and ultimately improve clinical care.
Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
